Published in Adv Exp Med Biol on January 01, 2000
A new chromogranin A-dependent angiogenic switch activated by thrombin. Blood (2012) 0.96
Cerebrospinal fluid levels of chromogranin A in the treatment-naïve early stage Parkinson's disease: a pilot study. J Neural Transm (Vienna) (2013) 0.84
Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med (1993) 2.61
The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med (1977) 2.28
Plasma atrial natriuretic peptide is unstable under most storage conditions. Circulation (1992) 2.24
Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest (1997) 1.86
Plasma noradrenaline increases with age. Nature (1976) 1.56
Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension (2000) 1.50
A more sensitive and specific radioenzymatic assay for catecholamines. Life Sci (1990) 1.50
Accelerated risk of hypertensive blood pressure recordings among Alzheimer caregivers. J Psychosom Res (1999) 1.47
Cardiac epinephrine synthesis. Regulation by a glucocorticoid. Circulation (1991) 1.46
Gender differences in autonomic cardiovascular regulation: spectral, hormonal, and hemodynamic indexes. J Appl Physiol (1985) (2001) 1.43
Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA. J Biol Chem (1997) 1.38
Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man. Life Sci (1976) 1.33
Circulating catecholamines and sympathetic activity after head injury. Neurosurgery (1981) 1.32
Increased sympathetic nervous system activity in alcoholic patients treated with disulfiram. Am J Psychiatry (1977) 1.28
Interleukin-6 and tumor necrosis factor-alpha production after acute psychological stress, exercise, and infused isoproterenol: differential effects and pathways. Psychosom Med (2000) 1.24
Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides (1998) 1.24
Age-adjusted plasma norepinephrine levels are similar in normotensive and hypertensive subjects. N Engl J Med (1977) 1.24
Development and validation of a noninvasive method to determine arterial pressure and vascular compliance. Am J Cardiol (1997) 1.22
High plasma norepinephrine levels in patients with major affective disorder. Am J Psychiatry (1982) 1.21
Relationship of arousals from sleep to sympathetic nervous system activity and BP in obstructive sleep apnea. Chest (1999) 1.19
Chromogranin A in human hypertension. Influence of heredity. Hypertension (1995) 1.18
Chromogranins A and B and secretogranin II: evolutionary and functional aspects. Acta Physiol (Oxf) (2007) 1.17
Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity in primary autism. Arch Gen Psychiatry (1977) 1.15
Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) (1991) 1.14
Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation (1990) 1.14
Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity. Mol Endocrinol (2000) 1.14
Molecular genetics of essential hypertension: recent results and emerging strategies. Curr Opin Nephrol Hypertens (2001) 1.13
Renal denervation in the rat: analysis of glomerular and proximal tubular function. Am J Physiol (1983) 1.13
Heredity and the autonomic nervous system in human hypertension. Curr Hypertens Rep (2000) 1.12
Chromogranin A. Storage and release in hypertension. Hypertension (1990) 1.12
Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem (1999) 1.12
Deficient sympathetic nervous response in familial dysautonomia. N Engl J Med (1976) 1.12
Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion. J Clin Invest (2000) 1.10
Proteolytic cleavage of chromogranin A (CgA) by plasmin. Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release. J Biol Chem (2001) 1.08
Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. J Clin Invest (1996) 1.08
Catecholamine storage vesicle protein expression in genetic hypertension. Blood Press (1999) 1.07
Adrenergic control of circulating lymphocyte subpopulations. Effects of congestive heart failure, dynamic exercise, and terbutaline treatment. J Clin Invest (1990) 1.06
Noradrenergic projections to the spinal cord of the rat. Brain Res (1983) 1.04
Arterial compliance by cuff sphygmomanometer. Application to hypertension and early changes in subjects at genetic risk. Hypertension (1996) 1.03
New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. Cell Mol Life Sci (2005) 1.03
Functional changes in neuropeptide Y- and somatostatin-containing neurons induced by limbic seizures in the rat. Neuroscience (1992) 1.03
Lymphocyte subset redistribution in response to acute experimental stress: effects of gender, ethnicity, hypertension, and the sympathetic nervous system. Brain Behav Immun (1995) 1.02
Norepinephrine and gamma-aminobutyric acid in amyotrophic lateral sclerosis. Neurology (1980) 1.01
Time-dependent effects of the neuropeptide PACAP on catecholamine secretion : stimulation and desensitization. Hypertension (1999) 1.01
The effect of sleep apnea on plasma and urinary catecholamines. Sleep (1995) 1.00
Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure. Kidney Int (2008) 0.99
Plasma norepinephrine, epinephrine, and thyroid hormone interactions in severely burned patients. Arch Surg (1980) 0.98
A sensitive radioenzymatic assay for catechol drugs. J Neurosci Res (1980) 0.98
Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules. J Biol Chem (2000) 0.98
Structure and function of the chromogranin A gene. Clues to evolution and tissue-specific expression. J Biol Chem (1991) 0.98
Alternating lateralization of plasma catecholamines and nasal patency in humans. Life Sci (1986) 0.97
Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element. J Clin Invest (1994) 0.97
Subtype-selective down-regulation of rat renal cortical alpha- and beta-adrenergic receptors by catecholamines. Endocrinology (1985) 0.97
Response of norepinephrine and blood pressure to stress increases with age. J Gerontol (1978) 0.96
Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP). J Clin Invest (1998) 0.96
Cerebrospinal fluid norepinephrine alterations during electrical stimulation of cerebellar, cerebral surfaces in epileptic patients. Neurology (1977) 0.95
What do plasma and urinary measures of catecholamines tell us about human response to stressors? Circulation (1991) 0.95
Beta2-adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in whites and African Americans. Am J Hypertens (2000) 0.95
Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function. J Neural Transm (Vienna) (2004) 0.94
Angiotensin II in adrenergic-induced alterations in glomerular hemodynamics. Am J Physiol (1984) 0.94
Plasma catecholamine and lymphocyte beta 2-adrenergic receptor alterations in elderly Alzheimer caregivers under stress. Psychosom Med (1997) 0.93
In vivo regulation of beta-adrenergic receptors on human mononuclear leukocytes: assessment of receptor number, location, and function after posture change, exercise, and isoproterenol infusion. J Clin Endocrinol Metab (1986) 0.93
Myocardial beta-adrenergic receptor expression and signal transduction after chronic volume-overload hypertrophy and circulatory congestion. Circulation (1992) 0.93
Sympatho-adrenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release. J Auton Pharmacol (1994) 0.92
Neuropeptide Y-mediated pressor responses following high-frequency stimulation of the rat sympathetic nervous system. J Pharmacol Exp Ther (1997) 0.91
Age-dependence of hypertensive-normotensive differences in plasma norepinephrine. Hypertension (1983) 0.91
Catecholamine secretory vesicles. Augmented chromogranins and amines in secondary hypertension. Hypertension (1993) 0.91
A crucial role for the mitogen-activated protein kinase pathway in nicotinic cholinergic signaling to secretory protein transcription in pheochromocytoma cells. Mol Pharmacol (1998) 0.91
Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson's disease and congenital dopamine beta-hydroxylase deficiency. Clin Sci (Lond) (1994) 0.91
Hypermetabolic low triiodothyronine syndrome of burn injury. Crit Care Med (1982) 0.90
Regulation of cardiac beta-adrenergic receptors by captopril. Implications for congestive heart failure. Circulation (1989) 0.90
Processing of chromogranin B in bovine adrenal medulla. Identification of secretolytin, the endogenous C-terminal fragment of residues 614-626 with antibacterial activity. Eur J Biochem (1995) 0.90
Regulation of plasminogen gene expression by interleukin-6. Blood (1997) 0.90
False positive head-up tilt: hemodynamic and neurohumoral profile. J Am Coll Cardiol (2000) 0.90
Bacterial endotoxin induces [Ca2+]i transients and changes the organization of actin in microglia. Glia (1994) 0.89
Glucocorticoid hypertension and nonadrenal phenylethanolamine N-methyltransferase. Hypertension (1993) 0.89
Does caffeine confound relationships among adrenergic tone, blood pressure and sleep apnoea? J Sleep Res (2000) 0.89